These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Salvage treatment with sole high-dose-rate endobronchial interventional radiotherapy (brachytherapy) for isolated endobronchial tumor recurrence in non-small-cell lung cancer patients: a 20-year experience.
    Author: Soror T, Kovács G, Fürschke V, Ismail M, Badakhshi H.
    Journal: Brachytherapy; 2019; 18(5):727-732. PubMed ID: 31227399.
    Abstract:
    PURPOSE: The purpose of this study was to report on the use of high-dose-rate (HDR) endobronchial interventional radiotherapy (brachytherapy) for isolated endobronchial tumor recurrence in patients with non-small-cell lung cancer, in whom a surgery or external radiation treatment is not possible. METHODS AND MATERIALS: A retrospective review of the patients with endobronchial tumors treated with HDR-endobronchial interventional radiotherapy at our institution (1995-2015) was performed. Treatment results and treatment-related toxicity were recorded. Clinical response was evaluated by bronchoscopy 3 months after treatment. Disease-free survival and overall survival were analyzed. RESULTS: One hundred twenty-six patients were identified. The median age was 63 years, and median followup time was 67.2 months. Three-month complete local response was 86.5%. At 5 years, disease-free survival was 41.4% and overall survival was 23.6%. 12.7% of the patients died from massive hemoptysis. CONCLUSION: HDR-endo brochial brachytherapy is an effective treatment option with acceptable toxicity for patients with endobronchial tumor recurrence in whom surgery and external beam radiotherapy are contraindicated.
    [Abstract] [Full Text] [Related] [New Search]